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Background: Given increasing rates of resistance to existing therapy, new options for treatment and prophylaxis of
malaria are needed.
Methods: Two randomised, comparative, non-inferiority studies were conducted in Africa, one double-blinded and
one open-label. Adults with fever, a positive peripheral blood smear, and a positive rapid diagnostic test for Plasmodium
falciparum were randomised in both studies to either azithromycin (AZ) 1,000 mg plus chloroquine (CQ) 600-mg base
(AZCQ 1,000 mg) once daily for three days or mefloquine hydrochloride (MQ) 1,250 mg (split dose). In the first study,
an additional regimen of AZ 500 mg plus CQ 600-mg base (AZCQ 500 mg) once daily for three days was included. All
study participants were hospitalised until three consecutive daily blood smears were negative for asexual P. falciparum
parasitaemia. Study participants were evaluated weekly for 42 days, with Day 28 polymerase chain reaction
(PCR)-corrected parasitological clearance rate as primary endpoint.
Results: A total of 467 subjects were randomised in the two studies. At 28 days’ follow-up, PCR-corrected
parasitological clearance rates in the per protocol population in the first study were 101/103 (98%) with AZCQ
1,000 mg compared with 102/103 (99%) with MQ (95% confidence interval [CI]: −5.2, 3.3). The AZCQ 500-mg
regimen was stopped during an interim study review (six [86%] clearance of seven evaluable; two lost to follow-up). In
the second study, clearance rates were similar: AZCQ 1,000 mg 107/107 (100%) vs MQ 111/112 (99%; 95% CI: −1.8, 3.6).
Among the participating countries, in vitro CQ resistance based on pfcrt mutation frequency in the baseline isolates
across both studies ranged from 20.8% (Zambia) to 96.1% (Uganda). Serious adverse events (AEs; all causality) were
observed more frequently with MQ compared with AZCQ (four vs one, respectively), though discontinuations for AEs
were similar (four vs three, respectively). Common AEs in the AZ-containing arms included pruritus, vomiting, dizziness,
and headache.
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Conclusions: Among adults with symptomatic uncomplicated falciparum malaria in Africa, the combination of AZ
1,000 mg and CQ 600-mg base once daily for three days resulted in Day 28 PCR-corrected parasitological clearance
rates of ≥98% and was non-inferior to treatment with MQ. AZCQ was well tolerated.
Trial registration: ClinicalTrials.gov identifiers NCT00082576 and NCT00367653
Keywords: Azithromycin, Chloroquine, Falciparum malaria, Combination treatmentBackground
Malaria remains one of the most common causes of
morbidity and mortality in Africa. In 2011, >80% of
the population in most countries in Africa were at
high risk for malaria [1]. The use of pesticides and the
broad availability of chloroquine (CQ) effectively con-
tained malaria on the African continent through the
1970s, until subsequent development of resistance by
the Plasmodium species led to increased morbidity
and mortality [2].
Management of malaria in Africa requires a variety
of preventive and treatment initiatives, each of which
targets different patient subpopulations. As a conse-
quence, these initiatives demand medical therapy that,
individually, vary in the requirements for safety, effi-
cacy, and tolerability and, collectively, must integrate
within a larger public health strategy. Increasing de-
grees of parasite resistance to mainstream drug inter-
ventions have further limited the choice of therapy
available for malaria [3]. For example, there is cur-
rently no generally acceptable alternative for sulpha-
doxine/pyrimethamine in the intermittent preventive
therapy in pregnancy programme. New therapy is
needed and alternative options must be explored for
their potential utility.
The anti-malarial properties of azithromycin (AZ)
have been documented in vitro and in animal experi-
ments, as well as in treatment and prevention clinical
trials of both Plasmodium falciparum and Plasmo-
dium vivax [4-8]. Given as monotherapy, AZ did not
meet clinical standards of efficacy for treatment of
falciparum malaria. However, further in vitro work
suggested the possibility of synergy between AZ and
CQ [4], which was subsequently supported by a small
clinical trial in India [6].
Given the need for a new anti-malarial therapy and
the scarcity of new potential agents, and the promis-
ing early results of a pilot clinical study [6], as well as
the well-established safety profiles of both agents,
there was a need to conduct a study to compare com-
bined AZ and CQ with mefloquine hydrochloride
(MQ). MQ was used as the comparator based on the
recommendation of the US Food and Drug Adminis-
tration (FDA). The results of two trials of the combin-
ation of AZ and CQ in the treatment of symptomaticuncomplicated P. falciparum malaria in adults in Af-
rica are reported here.
Methods
Study design
The two phase II/III multi-centre, parallel, randomised,
controlled, comparative, non-inferiority studies reported
here were performed sequentially. Study number
A0661134 (referred to hereafter as study 1134; Clinical-
Trials.gov identifier NCT00082576; double-blind phase
II/III) was conducted between June 2004 and May 2006,
and study number A0661155 (referred to hereafter as
study 1155; ClinicalTrials.gov identifier NCT00367653;
open-label phase III) was conducted between November
2006 and September 2007. Both studies were conducted
in African countries; study 1134 in Ghana, Mali, Zambia,
Kenya, and Uganda and study 1155 in Ghana, Mali,
Zambia, Kenya, Burkina Faso, and Senegal. In both tri-
als, the comparator agent was MQ and both studies
were identical in conduct and analysis with two excep-
tions. Study 1134 was conducted with blinded therapy
and initially included a third arm (AZ 500 mg plus a CQ
600-mg base [AZCQ 500 mg] once daily for three days),
whereas in study 1155 medication was provided un-
blinded with the same two treatment regimens as in
study 1134. As a consequence, the methods described
below relate to study conduct and analysis for both trials
with exceptions specifically noted where relevant.
Study population
Eligible subjects were ≥18 years of age with symptomatic
uncomplicated malaria as demonstrated by blood smears
positive for P. falciparum asexual parasitaemia between
1,000 and 100,000 parasites/μL and fever, documented
or by history, within the prior 24 hours. Subjects also
were required to have a serum glucose ≥60 mg/dL and a
rapid diagnostic test positive for P. falciparum. Women
of childbearing potential were required to have a nega-
tive urine human chorionic gonadotropin test before
study entry, and enrolled subjects were to use adequate
contraception during the entire study. Subjects were
excluded for any of the following reasons: clinical or
laboratory evidence of severe or complicated malaria;
the presence of non-falciparum species on microscopy;
pregnancy or breast-feeding; history of allergy or
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history of epilepsy or psoriasis; treatment with any anti-
malarial drug or with any antibacterial with known anti-
malarial activity within two weeks before enrolment
into the study; laboratory evidence of abnormal renal or
liver function; any major psychiatric disorders; inability
to swallow oral medication; treatment with other inves-
tigational drugs 30 days prior to enrolment; alcohol
and/or any other drug abuse; requirement to use medi-
cation during the study that might have interfered with
the evaluation of the study drug; other medical condi-
tions that would have interfered with the evaluation of
the therapeutic response or safety of the study drug; and
inability to comprehend and/or unwillingness to follow
the study protocol; or, prior participation in this study.
Finally, subjects were excluded if they had not lived
continuously in a malaria-endemic area for at least the
previous year.
Subjects were to be withdrawn from the study and
placed on alternative therapy for any of the following
reasons: impaired consciousness, respiratory distress,
seizures, hypoglycaemia, gross haematuria, increase in
parasitaemia to >100,000 parasites/μL 48 hours after the
first treatment dose, failure of parasitaemia to decrease
to 25% of the baseline value on Day 2 and investigator
opinion that other anti-malarial therapy was indicated or
treatment failure.
Drug treatment
Study drug was administered as blinded therapy with
matching placebo (in study 1134) or unblinded (in study
1155). In study 1134, eligible subjects were initially ran-
domised to oral treatment for three days in one of three
active treatment arms: AZ 1,000 mg plus a CQ 600-mg
base (AZCQ 1,000 mg) once daily for three days, AZ
500 mg plus a CQ 600-mg base (AZCQ 500 mg) once
daily for three days, or MQ (salt equivalent to 28-mg
free base) 1,250 mg (initial 750-mg dose followed by
500 mg on Day 0). In study 1155, subjects were randomised
to either AZCQ 1,000 mg once daily for three days or
MQ (salt equivalent to 28-mg free base) 1,250 mg
(initial 750-mg dose followed by 500 mg on Day 0). MQ
was used as the comparator based on the recommenda-
tion of the FDA, as this was the only FDA-approved oral
anti-malaria agent at the time. MQ was expected to
have high efficacy rates in all of the chosen study loca-
tions at the time of the study conduct.
Parasite identification
A blood dipstick-based test (Binax NOWW ICT,
Scarborough, ME, USA) was used for rapid diagnostic test-
ing of P. falciparum. Giemsa-stained blood smears were
read and interpreted by experienced microscopists who
were blinded to all clinical information, including treatmentallocation and the readings by the other microscopists.
Three slides were prepared for each subject; two of
these were read locally, whereas the third slide was
maintained for possible third party review in case of any
discordance ≥50% between the first two readers. Mi-
croscopy results at the site guided subject management;
any subject with persistent or recurrent parasitaemia
during the follow-up period was treated with anti-
malarial drugs according to local treatment guidelines
and withdrawn from the study after documentation of
clearance of parasitaemia.
For subjects who developed asexual parasitaemia after
a period of clearance, paired blood blots from baseline
and the time of recurrence were analysed to distinguish
recrudescence from re-infection. Genotyping was per-
formed by nested polymerase chain reaction (PCR) at
two different laboratories, the Naval Medical Research
Unit 2 in Jakarta, Indonesia (study 1134 only) and the
Malaria Research and Training Centre in Bamako, Mali
(both studies). In both studies, merozoite surface protein
(MSP)-1, MSP-2, and the microsatellite CA1 gene loci
(Su) were amplified at the Malaria Research and Train-
ing Centre. Recrudescence was defined as the reappear-
ance of asexual blood-stage parasites of the same
genotype as Day 0 parasites, whereas re-infection was
defined as infection by a different genotype. Subjects
were censored at the time of re-infection.
Paired blood specimens, collected before treatment and
at the time of recurrent asexual parasitaemia (treatment
failure), were evaluated for mutations in the P. falciparum
CQ resistance transporter gene (pfcrt). For study 1134,
molecular detection of the K76T mutation associated with
CQ resistance was detected by means of a standardised
real-time PCR-based diagnostic assay [9,10]. In addition,
specimens collected on Day 0 from subjects who
responded to treatment also were analysed for pfcrt
gene mutations. Based on differential melting-curve
analysis, isolates were identified as CQ-sensitive isolates
with a CVMNK haplotype or CQ-resistant isolates carry-
ing a CVIET, SVMNT, CVMNT, or CVMET haplotype.
For study 1155, nested PCR methods were performed
for pfcrt (K76T) and P. falciparum multi-drug resist-
ance protein-1 (pfmdr1; N86Y) with the specific pri-
mer pairs followed by restriction fragment length
polymorphism [11].
Study assessments
All subjects were hospitalised and monitored until three
consecutive blood smears were negative for asexual P.
falciparum parasitaemia and the investigator deemed
discharge from the hospital appropriate. Peripheral
blood smears for parasite counts were obtained at eight-
hour intervals until clearance was demonstrated, then
on Day 7 and weekly thereafter through Day 42 to
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symptoms, adverse events (AEs), and concomitant medi-
cations were assessed for all subjects on each day of treat-
ment (Days 0, 1, and 2) and at each post-therapy visit
(Days 7, 14, 21, 28, 35, and 42). Haematology and serum
chemistry laboratory tests were performed at Baseline and
Day 3 and at subsequent visits if clinically indicated.
Haematology tests included red blood count, white blood
count with differential, haemoglobin, haematocrit, and
platelets. Serum chemistry tests included electrolytes, urea
nitrogen, creatinine, aspartate aminotransferase, alanine
aminotransferase, and alkaline phosphatase.
Efficacy
The primary endpoint was the asexual P. falciparum para-
site clearance rate, adjusted for molecular testing (PCR-
corrected) to differentiate recrudescence (true failures)
from re-infection. Efficacy was assessed at Days 28 (pri-
mary endpoint) and 42 in the per protocol (PP) popula-
tion. Treated subjects were excluded from the PP
population if they did not meet the disease definition, did
not receive all three days of study medication (unless des-
ignated a treatment failure, defined as the development of
signs of severe malaria in the presence of parasitaemia),
or did not have a blood smear at the specified time point
(unless due to recurrent parasitaemia before that time
point). Subjects were assigned a response of eradicated if
parasitaemia cleared within seven days after initiation of
treatment and did not recur through the time point of inter-
est. Failure was defined as not achieving clearance of asexual
P. falciparum parasitaemia within seven days or, if after
achieving clearance, PCR-corrected parasitaemia recurred.
Secondary efficacy analyses included time required for
asexual parasite clearance, fever clearance time, and as-
sessment of the percentage of subjects with early and
late treatment failures as defined by the World Health
Organization [12].
Safety
All subjects who received at least one dose of study
medication were evaluated for safety. Subjects were
monitored closely for clinical evidence of illness progres-
sion. All subjects with persistent or recurrent parasitaemia
received therapy consistent with the local standard of care
and were monitored until parasite clearance was docu-
mented. Other safety evaluations included AE and vital
sign monitoring throughout the study, haematology and
serum chemistry laboratory evaluations, and physical
examinations.
Statistical analyses
The primary efficacy analysis compared the PCR-corrected
asexual P. falciparum parasite clearance rates in the AZCQ
1,000 mg and MQ treatment arms at Day 28 in the PPpopulation. A two-sided confidence interval (CI), using the
appropriate confidence level, was constructed for the differ-
ence between treatment groups in asexual parasite clear-
ance rates using normal approximation to the binomial,
and also for within group rates. A CI was computed for the
clearance rate within a treatment group using exact
methods when no failures were observed. The confidence
level in the final analysis for study 1134 required a small ad-
justment upward from 95 to 95.04% to prevent the overall
false-positive rate from exceeding 0.05, due to the planned
interim analysis of the primary efficacy outcome. There was
no adjustment for centres in the analyses. Non-inferiority
was to be concluded if the lower boundary of the CI for the
difference in parasite clearance rates (AZCQ 1,000 mg –
MQ) was −10% or more. A non-inferiority margin of 10%
was based on regulatory guidance available at the time of
study conception. Clearance time comparisons up to Day 7
were generated using Kaplan-Meier estimates. Parasite
clearance time was defined as the time in days from Base-
line to the first of the three consecutive zero parasite
counts. Fever clearance time was defined as the time in
days from Baseline to the first of the two consecutive time
points without evidence of elevated temperature.
Total sample size was determined based on the follow-
ing assumptions: 80% power to show non-inferiority of
the AZCQ 1,000-mg arm relative to the MQ arm, 85%
of randomised subjects satisfying criteria for inclusion in
the PP analysis at the Day 28 visit, and expected parasite
clearance rates of 95% in the AZCQ 1,000-mg arm and
95% in the MQ arm.
These studies were conducted in compliance with the
Declaration of Helsinki, institutional review boards, in-
formed consent regulation, and the International Confer-
ence on Harmonisation Good Clinical Practice guidelines.
All local regulatory requirements were followed. The
clinical protocol was conducted in accordance with FDA
regulations. Pfizer Inc conducted the clinical monitoring
of the study.
Results
A total of 467 subjects were randomised to study medi-
cation (Figure 1). The demographic and baseline charac-
teristics of subjects were similar among treatment
allocations (Table 1). Similar numbers of subjects on
each regimen completed therapy.
The AZCQ 500-mg regimen was stopped early in study
1134 on the recommendation of the data safety monitor-
ing board after a review of data from studies conducted in
South America and India demonstrated a dose response
with lower efficacy rates for this regimen compared with
AZCQ 1,000 mg. At that point, a total of nine subjects
had been randomised to the AZCQ 500-mg regimen, of
which six of seven subjects in the PP population had














Figure 1 (See legend on next page.)
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Figure 1 Subject disposition in study 1134 (A) and study 1155 (B). aThe AZCQ 500-mg regimen was not included in the analysis, as treatment
was stopped early on the recommendation of the data safety monitoring board after a review of data from studies conducted in South America and
India demonstrated a dose response with lower efficacy rates for this regimen compared with AZCQ 1,000 mg. AE, adverse event; AZCQ 1,000 mg,
azithromycin 1,000 mg plus chloroquine 600-mg base; AZCQ 500 mg, azithromycin 500 mg plus chloroquine 600-mg base; MQ, mefloquine
hydrochloride; PP, per protocol.
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during the follow-up period were to receive rescue therapy
with an anti-malarial regimen that was consistent with the
local standard of care. Ten and five subjects treated with
AZCQ and five and three patients treated with MQ in
studies 1134 and 1155, respectively, received rescue medi-
cation. The most common rescue mediation used was
quinine in both treatment groups.
Among study 1134 PP population subjects at Day 28,
those randomised to AZCQ 1,000 mg had 98.1% para-
site clearance (94.9, 100 95.04% CI; n = 101 of 103)
compared with 99.0% parasite clearance (96.7, 100
95.04% CI; n = 102 of 103) in those who received MQ
based on PCR-corrected results (Table 2; difference, −0.97%
[95.04% CI: −5.2, 3.3]). For corresponding PCR-
uncorrected results, those randomised to AZCQ 1,000 mg
had 95.1% parasite clearance (90.5, 99.8 95.04% CI; n = 98
of 103) compared with 98.1% parasite clearance (94.9, 100












Mean (SD) 29.4 (9.6)
Weight, kg
Mean (SD) 61.4 (10.8)
Range 40.0-105.0
Baseline parasite count/μL, mean ± SD 20,889 ± 24,176
Range 160-111,040





aOne subject <18 years of age.
AZCQ 1,000 mg, azithromycin 1,000 mg plus chloroquine 600-mg base; MQ, mefloqDay 42, 99% parasite clearance was observed in both
groups (PCR-corrected; 96.6, 100 95.04% CI; n = 100 of
101 AZCQ; 96.6, 100 95.04% CI; n = 100 of 101 MQ; dif-
ference, 0% [95.04% CI: −3.74, 3.74]).
The rate of gametocyte clearance was similar in both
AZCQ and MQ groups in both studies and was >95%
from Day 7 onwards.
The median time to clearance of asexual P. falciparum
parasitaemia was 48 hours for those given AZCQ
1,000 mg and 36 hours for those given MQ (p = 0.0226).
Median time to resolution of fever was observed to
be <0.5 days after starting therapy for subjects rando-
mised to AZCQ 1,000 mg and 0.5 days for those given
MQ.
Similar findings were observed in study 1155, whereas
subjects in the PP population randomised to AZCQ
1,000 mg had 100% parasite clearance (96.6, 100 95% CI;
n = 107 of 107) compared with 99.1% (96.9, 100 95% CI;















30.2 (11.0) 30.2 (11.0) 31.2 (12.4)
60.4 (11.0) 60.0 (9.9) 59.4 (10.1)
39.0-107.0 40.0-83.6 39.0-94.0






uine hydrochloride; SD, standard deviation.
Table 2 Summary of efficacy outcomes at Day 28 in the
parasitological per protocol population
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−0.97 (−5.23, 3.29)a 0.89 (−1.77, 3.56)
ETF, n (%) 0 1 (1.0) 0 1 (0.9)
LTF, n (%) 2 (1.9) 0 0 0
LPF, n (%) 2 0 0 0
LCF, n (%) 0 0 0 0
Median fever
clearance time, days
<0.5 0.5 1.5 1.0
Median parasite
clearance time, h
48 36 44 40
a95.04% CI (small adjustment to the 95% CI required in order to account for a
planned interim look at the primary efficacy outcome).
AZCQ 1,000 mg, azithromycin 1,000 mg plus chloroquine 600-mg base;
CI, confidence interval; ETF, early treatment failure; LCF, late clinical failure;
LPF, late parasitological failure; LTF, late treatment failure; MQ, mefloquine
hydrochloride; PCR, polymerase chain reaction; PP, per protocol.
Table 3 Markers of chloroquine resistance in isolates
obtained during the clinical trial
Number of
subjects
Pfcrt Resistance mutations, %
Tested K T KT Noband 2004-2006a 2006-2007b
Ghana
Study 1134 27 11 16 0 0 59.3
Study 1155 83 52 25 3 3 33.7
Uganda
Study 1134 51 1 49 0 1 96.1
Study 1155
Zambia
Study 1134 116 85 26 5 0 26.7
Study 1155 77 61 13 3 0 20.8
Mali
Study 1134 27 8 18 0 1 66.7
Study 1155 29 5 20 4 0 82.8
Burkina Faso
Study 1134
Study 1155 27 19 7 0 1 25.9
Kenya
Study 1134 15 2 10 0 3 66.7
Study 1155 7 1 5 0 1 71.4
Senegal
Study 1134
Study 1155 6 3 2 1 0 50.0
aStudy 1134.
bStudy 1155.
K, wild type; KT, mixed; pfcrt, Plasmodium falciparum chloroquine resistance
transporter gene; T, resistant.
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PCR-uncorrected results, subjects in both the AZCQ
1,000-mg (96.8, 100 95% CI; n = 106 of 107) and MQ
(96.9, 100 95% CI; n = 111 of 112) groups had a 99.1%
parasite clearance. At Day 42, PCR-corrected parasite
clearance remained at 100% for the AZCQ group (96.5, 100
95% CI; n = 104 of 104) and 99.1% for the MQ group (96.9,
100 95% CI; n = 110 of 111; difference, 0.90% [95%
CI: −1.8, 3.6]).
The median time to clearance of parasitaemia was
44 hours for subjects given AZCQ 1,000 mg and
40 hours for those given MQ. Median time to resolution
of fever was observed to be 1.5 days after starting ther-
apy for subjects randomised to AZCQ 1,000 mg and
1 day for those given MQ, although the difference was
not statistically significant.
Two late parasitological failures (LPFs) were observed
in study 1134 for subjects in the AZCQ 1,000-mg treat-
ment group (Table 2), whereas there were no LPFs in
the MQ treatment group. No LPFs were observed in
study 1155 in either treatment group.
Paired isolates from the two subjects who demonstrated
a recrudescence on AZCQ 1,000 mg were sequenced to
identify possible signature resistance mutations. No such
mutations were identified [13]. CQ–resistance-associated
mutation rates varied among the countries participating in
these studies, from 96.1% in Uganda (study 1134) to 20.8%
in Zambia (study 1155; Table 3). An analysis of isolatescollected during study 1134 indicated that 13% (15/115) of
CQ-resistant isolates carried the CVMNT pfcrt haplotype
(Table 4).
Treatment-emergent AEs considered related to study
medication were observed in 78.1% (89/114) of subjects
randomised to AZCQ 1,000 mg and in 61.7% (71/115)
of those randomised to MQ in study 1134, and in 70.8%
(80/113) and 62.1% (72/116) of subjects, respectively, in
study 1155 (Table 5). Pruritus was seen more frequently
with AZCQ 1,000 mg, whereas dizziness was seen more
often with MQ (Table 5). Overall, three (1.3%) subjects
given AZCQ 1,000 mg discontinued therapy due to an AE
related to study drug (vomiting, pruritus, vomiting/dizzi-
ness/tinnitus) compared with two (0.9%) of those receiving
MQ (fever/hypotension/haematuria, hypertension/vomi-
ting). No clinically significant changes were observed in
any laboratory values over the duration of the study and
abnormal laboratory values did not result in any study dis-
continuations (see Additional files 1 and 2).








CQ-sensitive, n 48 59
CVMNK 48 58
SVMNK 0 1




Negative, n 3 2
Other, n 0 1
AZCQ 1,000 mg, azithromycin 1,000 mg plus chloroquine 600-mg base; CQ,
chloroquine; MQ, mefloquine hydrochloride; pfcrt, Plasmodium falciparum CQ
resistance transporter gene.
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were only observed in the MQ group (3/231 [1.3%];
mental disorder, nephrotic syndrome/blood creatinine
increased and intentional self-injury). A severe AE of
vomiting was seen in one (0.4%) subjects given AZCQ
1,000 mg, whereas six severe AEs were observed in five
(2.2%) subjects given MQ (vomiting, increased creati-
nine, psychosis, intentional self-injury, nephrosis, and
dizziness). The majority of all other AEs with AZCQ
1,000 mg and MQ were mild in severity.
Discussion
The fixed-dose combination of AZ 1,000 mg and a CQ
600-mg base was found to be non-inferior to MQ
in two randomised studies conducted in Africa in






Any AE, n (%) 89 (78.1) 71 (6
Pruritus 58 (50.9) 11 (9
Dizziness 11 (9.6) 26 (2
Vomiting 18 (15.8) 12 (1
Headache 15 (13.2) 11 (9
Abdominal pain 8 (7.0) 13 (1
Nausea 9 (7.9) 13 (1
Asthenia 6 (5.3) 11 (9
Palpitations 3 (2.6) 7 (6
Diarrhoea 6 (5.3) 5 (4
Fatigue – –
Pain 2 (1.8) 2 (1
AE, adverse event; AZCQ 1,000 mg, azithromycin 1,000 mg plus chloroquine 600-mP. falciparum. In addition to similar clinical and parasito-
logical outcomes, the AZCQ fixed-dose combination also
achieved an overall efficacy rate of 99%, which is consist-
ent with other treatment modalities recommended in
treatment guidelines for this subject population [12]. The
mean time to resolution of parasitaemia was comparable
in each regimen, as was the time to resolution of fever.
A pre-specified non-inferiority margin of 10% was based
on regulatory guidance at the time of study conception.
Although this margin has been used by other phase III tri-
als as recent as 2011, many trials of late have switched to a
more conservative margin of 5% [14]. Given the level of
parasite clearance achieved at Day 28 in studies 1134 and
1155, lower limits of the CIs comparing the two treat-
ments would indicate a difference relative to MQ of no
worse than 5.23% and 1.77%, respectively.
In Zambia, the rate of clinical resistance to CQ
was >70% in 2003 at the time of switching from CQ to
artemether/lumefantrine. Based on this observation, it
is clear that AZCQ displayed efficacy in areas with a
high prevalence of CQ-resistant falciparum malaria.
Molecular marker resistance to CQ across these seven
African countries between 2004 and 2007 ranged from
approximately 21 to 96%. There was a trend to lower
rates of CQ resistance in the clinical trial sites in Ghana
and Zambia over this time period, which may be related
to anti-malarial policies in these countries vs the other
countries included in this study.
The pfcrt CQ-resistant haplotype most frequently
described in Africa has been CVIET, which is thought to
have possibly been introduced from southeast Asia through
India [10]. As previously reported, the CVIET haplotype
was again observed in this study. Notably, 13% of isolates in








1.7) 80 (70.8) 72 (62.1)
.6) 32 (28.3) 1 (0.9)
2.6) 18 (15.9) 19 (16.4)
0.4) 4 (3.5) 20 (17.2)
.6) 20 (17.7) 25 (21.6)
1.3) 13 (11.5) 9 (7.8)
1.3) 10 (8.8) 12 (10.3)
.6) 9 (8.0) 3 (2.6)
.1) – –
.3) 11 (9.7) 4 (3.4)
4 (3.5) 6 (5.2)
.7) 6 (5.3) 1 (0.9)
g base; MQ, mefloquine hydrochloride.
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CVMNT CQ-resistant mutations have been previously ob-
served in Africa [15,16].
While no CQ monotherapy control arm was included
in this trial, the historical rates of clinical response to
CQ in areas with significant in vitro CQ resistance
would be expected to be significantly lower than those
observed on this combination therapy [17]. Whether the
enhanced efficacy of the combination is a consequence
of the direct effects of AZ on the parasite or the effect of
AZ on the resistance mechanisms mediating CQ resist-
ance, or both, cannot be established from these data.
Moreover, anti-malarial immunity in malaria-endemic
areas also can assist in parasite clearance and may play a
role in the enhanced efficacy of the combination therapy,
although innate immunity is equally likely to be effective in
those subjects who received either AZ or CQ alone [18].
Discontinuations due to AEs were infrequent and
numbers were similar in each regimen. Pruritus was seen
more frequently with the AZCQ combination, a well-
described effect associated with the use of CQ in subjects
with melanoderma [19]. Central nervous system AEs were
seen more frequently with MQ, and again this is consis-
tent with historical experience [20]. Gastrointestinal AEs
occurred with both regimens to a similar degree.
For a regimen to be considered appropriate as a ther-
apy for malaria, it first must demonstrate that it is safe
and effective in the target subject population. Other con-
siderations, however, should be addressed with regard to
the AZCQ combination. CQ is no longer recommended
for the treatment of malaria in Africa due to the generally
high rates of background CQ resistance and subsequent
poor clinical response to therapy throughout the contin-
ent. The position of the World Health Organization is that
all therapy for the treatment of malaria should be combi-
nation therapy, primarily combinations that include an ar-
temisinin derivative [21]. The combination therapy should
include a partner drug with sufficient efficacy to protect
the artemisinin from the development of resistance. Alter-
natively, new modelling suggests that the introduction of a
variety of therapy may be more effective in managing the
rate at which resistance appears [22].
A limitation of this study was the recruitment of
adults with symptomatic uncomplicated malaria only
and thus, other target populations, including pregnant
women, should be studied, as it is known that pregnant
women are more susceptible to malaria compared with
non-pregnant women within the same age group [23].
The progressive decline in the efficacy of sulphadoxine/
pyrimethamine in Africa, concerns with artemisinin use
in pregnancy [12], and the extensive safety database for
both AZ and CQ suggest that studies to investigate the
merits of this combination for the prevention of malaria
during pregnancy would appear justified [24]. Otherareas of study also may include use in the paediatric
population and, given the activity of AZ in a variety of
bacterial infections [25,26], home-based management of
fever.
A phase III trial (ClinicalTrials.gov identifier
NCT01103063) that evaluated a blended tablet of AZ and
CQ for intermittent preventive treatment of malaria in
pregnancy was stopped early, as an interim analysis indi-
cated it was unlikely to meet the primary endpoint (i.e.,
stopped for trial futility) defined as superiority of AZCQ
over sulfadoxine/pyrimethamine in the proportion of pa-
tients meeting a sub-optimal pregnancy outcome (abortion
[≤28 weeks], stillbirth [>28 weeks], premature delivery
[<37 weeks], low birth weight [<2,500 g] live neonate, miss-
ing neonatal birth weight, or lost to follow-up). As the pri-
mary endpoint was analysed using the intent-to-treat
population, lack of tolerability of the combination treatment
may have resulted in a higher dropout rate leading to the
inclusion of missing data as a failure in the interim analysis.
New therapy for the prevention and treatment of mal-
aria in the context of a broader campaign of public
health interventions is, therefore, needed to help limit
the morbidity and mortality associated with this disease.
Conclusions
The results of this study indicate that among adults
with symptomatic uncomplicated falciparum malaria in
Africa, a fixed-dose combination of AZ 1,000 mg and a
CQ 600-mg base once daily for three days resulted in
Day 28 and Day 42 PCR-corrected parasitological clear-
ance rates of ≥98%. AZCQ was non-inferior to treatment
with MQ and was well tolerated.
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